Loading...
Derniers dépôts
-
Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, Marie Attard, Claire Bournaud, et al.. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131 I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated thyroid Cancer. Clinical Cancer Research, 2023, 29 (13), pp.2401-2409. ⟨10.1158/1078-0432.CCR-23-0046⟩. ⟨inserm-04552345⟩
-
Grégoire Marret, Stéphane Temam, Maud Kamal, Caroline Even, Jean-Pierre Delord, et al.. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity. Scientific Reports, 2023, 13, pp.22524. ⟨10.1038/s41598-023-49887-4⟩. ⟨hal-04543900⟩
-
Charlotte Demoor-Goldschmidt, Stéphane Supiot, Marc-André Mahé, Odile Oberlin, Rodrigue Allodji, et al.. Clinical and histological features of second breast cancers following radiotherapy for childhood and young adult malignancy. British Journal of Radiology, 2018, 91 (1086), pp.20170824. ⟨10.1259/bjr.20170824⟩. ⟨inserm-04439735⟩
-
Imène Mansouri, Rodrigue S Allodji, Catherine Hill, Chiraz El‐fayech, François Pein, et al.. The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer. European Journal of Heart Failure, 2018, 21 (4), pp.509 - 518. ⟨10.1002/ejhf.1376⟩. ⟨inserm-04439245⟩
-
Manon de Vries-Brilland, Nathalie Rioux-Leclercq, Maxime Meylan, Jonathan Dauvé, Christophe Passot, et al.. Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma. Journal for Immunotherapy of Cancer, 2023, Journal for ImmunoTherapy of Cancer, 11 (11), pp.e006885. ⟨10.1136/jitc-2023-006885⟩. ⟨hal-04341909⟩
-
Thomas Grinda, Alison Antoine, William Jacot, Paul-Henri Cottu, Thibault de la Motte Rouge, et al.. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. European Journal of Cancer, 2023, 189, pp.112935. ⟨10.1016/j.ejca.2023.05.023⟩. ⟨hal-04205902⟩
-
Alexandre Bertucci, F. Bertucci, Christophe Zemmour, Florence Lerebours, Jean-Yves Pierga, et al.. PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. Frontiers in Oncology, 2020, 10, ⟨10.3389/fonc.2020.575978⟩. ⟨hal-03623650⟩
-
D. Dano, A. Lardy-Cleaud, A. Monneur, N. Quenel-Tueux, C. Levy, et al.. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). ESMO Open, 2021, 6 (4), pp.100220. ⟨10.1016/j.esmoop.2021.100220⟩. ⟨hal-03426433⟩
-
Clémence Romeo, Olivia Le Saux, Margaux Jacobs, Florence Joly, Gwenael Ferron, et al.. Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network. Cancers, 2022, 14 (2), pp.354. ⟨10.3390/cancers14020354⟩. ⟨hal-03622814⟩
-
Tina Lamy, Bastien Cabarrou, David Planchard, Xavier Quantin, Sophie Schneider, et al.. Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience. Cancers, 2021, 14 (1), pp.92. ⟨10.3390/cancers14010092⟩. ⟨hal-04142072⟩
-
Victoria Corvest, Perrine Marec-Bérard, Cyril Lervat, Hélène D. Pacquement, Maud Toulmonde, et al.. Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France. International Journal of Cancer, 2023, 152 (8), pp.1659-1667. ⟨10.1002/ijc.34326⟩. ⟨hal-04122360⟩